Stockwatch: Earnings Season Turns Into Silly Season
Executive Summary
A clinical trial failure at Auris and a revoked patent at Johnson & Johnson that will lead to the emergence of real US biosimilar competition passed virtually unnoticed last week. It's that time of year again.
You may also be interested in...
Stock Watch: Bridgebio’s Endpoint A Bridge Too Far
The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.
Stockwatch: A Biopharma Nativity Play
The cadence of the news in the biopharmaceutical space slowed significantly last week in the run-up to the holidays. In seasonal spirit, Andy “the innkeeper” Smith assigns roles in the Christmas nativity play to those who did come forward – including Ophthotech, Amicus and Lilly.
Auris' Outlook Bleak In Tinnitus After Failure Of Initial Phase III Trial
The Swiss biotech still holds out hope that its NMDA antagonist Keyzilen will hit its primary endpoint in a European Phase III study in acute tinnitus, but a largely US-based first Phase III trial missed both co-primary endpoints.